Alivus Life Sciences growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY24Mar 2024FY23Mar 2023
+5.6%+1.8%
+5.0%+4.3%
+3.4%+3.8%
+0.8%+11.5%
—+7.0%
+5.5%+9.4%
+9.1%+4.1%
+31.9%−47.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALIVUS₹1,397.40

Alivus Life Sciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAARTIDRUGSAKUMSAGARWALEYEAPLLTDADVENZYMESAARTIPHARMCORONA
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Last 12M
30/09/2026
Revenue Growth—+1.8+5.6—
EBITDA Growth—+4.3+5.0—
EBIT Growth—+3.8+3.4—
Net Income Growth—+11.5+0.8—
EPS Growth—+7.0——
Total Assets Growth—+9.4+5.5—
Total Equity Growth—+4.1+9.1—
Cash from Operations Growth—-47.6+31.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.